β-Catenin overexpression is associated with gefitinib resistance in non-small cell lung cancer cells

Pulmonary Pharmacology and Therapeutics

Volumn 28, Issue 1, 2014, Pages 41-48

  Fang, Xia ^a   Gu, Pan ^a   Zhou, Caicun ^a   Liang, Aibin ^a   Ren, Shenxiang ^a   Liu, Fang ^a   Zeng, Yu ^a   Wu, Yunjin ^a   Zhao, Yinmin ^a   Huang, Binbin ^a   Zhang, Zongmei ^a   Yi, Xianghua ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Epidermal growth factor receptor; Gefitinib; Non small cell lung cancer; Resistance; Tyrosine kinase inhibitors; catenin

Indexed keywords

BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ARTICLE; CELL SURVIVAL; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LUNG CANCER CELL LINE; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BETA CATENIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84900560653     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2013.05.005     Document Type: Article

References (31)

1. Sun S., Schiller J.H., Gazdar A.F. Lung cancer in never smokers-a different disease. Nat Rev Cancer 2007, 7:778-790.
2. Minna J.D., Roth J.A., Gazdar A.F. Focus on lung cancer. Cancer Cell 2002, 1:49-52.
3. Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-lable, randomised, phase 3 study. Lancet Oncol 2011, 12:735-742.
4. Zhou S., Ren S., Yan L., Zhang L., Tang L., Zhang J., et al. Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer. Respirology 2009, 14:709-715.
5. Ren S., Kuang P., Zheng L., Su C., Li J., Li B., et al. Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma. Cell Biochem Biophys 2012, 64:155-160.
6. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352:786-792.
7. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
8. Mazieres J., He B., You L., Xu Z., Jablons D.M. Wnt signaling in lung cancer. Cancer Lett 2005, 222:1-10.
9. Polakis P. Wnt signaling and cancer. Genes Dev 2000, 14:1837-1851.
10. Akiri G., Cherian M.M., Vijayakumar S., Liu G., Bafico A., Aaronson S.A. Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma. Oncogene 2009, 28:2163-2172.
11. Suzuki M., Shigematsu H., Nakajima T., Kubo R., Motohashi S., Sekine Y., et al. Synchronous alterations of Wnt and epidermal growth factor receptor signaling pathways through aberrant methylation and mutation in non small cell lung cancer. Clin Cancer Res 2007, 13:6087-6092.
12. Chen L., Huang K., Han L., Shi Z., Zhang K., Pu P., et al. β-catenin/Tcf-4 complex transcriptional regulates AKT1 in glioma. Int J Oncol 2011, 39:883-890.
13. Shih J.Y., Gow C.H., Yang P.C. EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer. N Engl J Med 2005, 353:207-208.
14. Cappuzzo F., Magrini E., Ceresoli G.L., Bartolini S., Rossi E., Ludovini V., et al. AKT phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2004, 96:1134-1141.
15. Li H., Schmid-Bindert G., Wang D., Zhao Y., Yang X., Su B., et al. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines. Adv Med Sci 2011, 56:275-284.
16. Cui J., Jiang W., Wang S., Wang L., Xie K. Role of Wnt/β-catenin signaling in drug resistance of pancreatic cancer. Curr Pharm Des 2012, 18:2464-2471.
17. Lobo N.A., Shimono Y., Qian D., Clarke M.F. The biology of cancer stem cells. Annu Rev Cell Dev Biol 2007, 23:675-699.
18. Keizumi F., Shimoyama T., Taguchi F., Saijo N., Nishio K. Establishment of a human non-small cell lung cancer cell line resistance to gefitinib. Int J Cancer 2005, 116:36-44.
19. Ju L., Zhou C., Li W., Yan L. Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. J Cell Biochem 2010, 111:1565-1574.
20. Liu C., Li Y., Semenov M., Han C., Baeg G.H., Tan Y., et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002, 108:837-847.
21. Behrens J., Jerchow B.A., Wurtele M. Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science 1998, 280:596-599.
22. Kondo Y., Kanai Y., Sakamoto M., Genda T., Mizokami M., Uede R., et al. Beta-catenin accumulation and mutation of exon 3 of the beta-catenin gene in hepatocellular carcinoma. Jpn J Cancer Res 1999, 90:1301-1309.
23. Kim H., Yoo S.B., Sun P., Jin Y., Jheon S., Lee C.T., et al. Alteration of the E-cadherin/β-catenin complex is an independent poor prognostic factor in lung adenocarcinoma. Korean J Pathol 2013, 47:44-51.
24. Yuan G., Regel I., Lian F., Friedrich T., Hitkove I., Hofheinz R.D., et al. WNT6 is a novel target gene of caveolin-1 promoting chemoresistance to epirubicin in human gastric cancer cells. Oncogene 2013, 32:375-387.
25. Kendziorra E., Ahlborn K., Spitzner M., Rave-Fränk M., Emons G., Gaedcke J., et al. Silencing of the Wnt transcription factor TCF4 sensitizes colorectal cancer cells to (chemo-) radiotherapy. Carcinogenesis 2011, 32:1824-1831.
26. Dieudonné F.X., Marion A., Marie P.J., Modrowski D. Targeted inhibition of TCF activity promotes syndecan-2 expression and sensitization to doxorubicin in osteosarcoma cells and bone tumors in mice. J Bone Miner Res 2012, 27:2118-2129.
27. Heidel F.H., Bullinger L., Feng Z., Wang Z., Neff T.A., Stein L., et al. Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell 2012, 10:412-424.
28. Yoo S.B., Kim Y.J., Kim H., Jin Y., Sun P.L., Jheon S., et al. Alteration of the E-cadherin/β-catenin complex predicts poor response to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment. Ann Surg Oncol 2013, [in press].
29. Faivre E.J., Lange C.A. Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells. Mol Cell Biol 2007, 27:466-480.
30. Jeon S.H., Yoon J.Y., Park Y.N., Jeong W.J., Kim S., Jho E.H., et al. Axin inhibits extracellular signal-regulated kinase pathway by Ras degradation via beta-catenin. J Biol Chem 2007, 282:14482-14492.
31. Yue X., Lan F., Yang W., Yang Y., Han L., Zhang A., et al. Interruption of β-catenin suppresses the EGFR pathway by blocking multiple oncogenic targets in human glioma cells. Brain Res 2010, 1366:27-37.